Health Catalyst, Inc. (NASDAQ:HCAT) Expected to Announce Quarterly Sales of $65.88 Million

Brokerages predict that Health Catalyst, Inc. (NASDAQ:HCATGet Rating) will announce $65.88 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Health Catalyst’s earnings, with the highest sales estimate coming in at $66.77 million and the lowest estimate coming in at $65.11 million. Health Catalyst reported sales of $55.85 million in the same quarter last year, which indicates a positive year-over-year growth rate of 18%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Health Catalyst will report full year sales of $290.59 million for the current fiscal year, with estimates ranging from $290.00 million to $291.49 million. For the next fiscal year, analysts expect that the company will post sales of $348.69 million, with estimates ranging from $344.68 million to $352.12 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Health Catalyst.

Health Catalyst (NASDAQ:HCATGet Rating) last released its quarterly earnings results on Tuesday, March 1st. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.02. The firm had revenue of $64.72 million for the quarter, compared to analysts’ expectations of $63.17 million. Health Catalyst had a negative net margin of 63.33% and a negative return on equity of 21.30%. The business’s revenue was up 21.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.41) EPS.

Several research analysts have weighed in on the stock. BTIG Research lowered their price target on shares of Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Friday, March 25th. SVB Leerink decreased their target price on shares of Health Catalyst from $64.00 to $48.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 2nd. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $66.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 2nd. Raymond James decreased their target price on shares of Health Catalyst from $70.00 to $40.00 and set a “strong-buy” rating on the stock in a research report on Friday, March 4th. Finally, The Goldman Sachs Group assumed coverage on shares of Health Catalyst in a research report on Friday, February 11th. They set a “buy” rating and a $48.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $44.29.

In related news, General Counsel Daniel H. Orenstein sold 4,112 shares of Health Catalyst stock in a transaction on Thursday, March 3rd. The shares were sold at an average price of $26.82, for a total transaction of $110,283.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Paul Horstmeier sold 5,208 shares of Health Catalyst stock in a transaction on Tuesday, April 12th. The stock was sold at an average price of $25.16, for a total transaction of $131,033.28. Following the transaction, the chief operating officer now directly owns 180,316 shares of the company’s stock, valued at approximately $4,536,750.56. The disclosure for this sale can be found here. Insiders have sold 47,097 shares of company stock valued at $1,234,764 in the last ninety days. Insiders own 2.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rock Springs Capital Management LP increased its stake in Health Catalyst by 8.3% in the third quarter. Rock Springs Capital Management LP now owns 850,000 shares of the company’s stock valued at $42,509,000 after purchasing an additional 65,000 shares in the last quarter. Credit Suisse AG grew its holdings in shares of Health Catalyst by 23.9% during the third quarter. Credit Suisse AG now owns 288,925 shares of the company’s stock valued at $14,448,000 after buying an additional 55,642 shares during the last quarter. Summit Global Investments acquired a new position in shares of Health Catalyst during the third quarter valued at about $290,000. Segall Bryant & Hamill LLC grew its holdings in shares of Health Catalyst by 1.5% during the third quarter. Segall Bryant & Hamill LLC now owns 617,232 shares of the company’s stock valued at $30,953,000 after buying an additional 8,951 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in shares of Health Catalyst by 25.6% during the third quarter. Teacher Retirement System of Texas now owns 6,037 shares of the company’s stock valued at $302,000 after buying an additional 1,231 shares during the last quarter.

Health Catalyst stock opened at $23.81 on Friday. The stock has a market cap of $1.24 billion, a P/E ratio of -7.42 and a beta of 0.89. The company has a quick ratio of 5.46, a current ratio of 5.46 and a debt-to-equity ratio of 0.35. Health Catalyst has a twelve month low of $20.39 and a twelve month high of $59.50. The company’s 50-day moving average price is $25.95 and its two-hundred day moving average price is $36.24.

About Health Catalyst (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Featured Stories

Get a free copy of the Zacks research report on Health Catalyst (HCAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.